Company intelligence / Profile preview

48Hour Discovery

Edmonton, Alberta, Canada48hourdiscovery.com ↗

Ownership: Private
Development stage: Preclinical

Overview

48Hour Discovery has developed a proprietary platform for rapid identification and optimization of high-affinity, high-specificity peptide leads using chemically modified phage display. The company’s pipeline is in preclinical stages, with a focus on cancer targets such as PD-L1 and EpCAM. They have demonstrated the ability to generate novel radiopeptide-based theranostics and have ongoing collaborations with major pharma companies. No clinical results are available yet.

Therapeutic areas: Oncology
Modalities: PeptidesBicyclic peptidesMacrocyclic peptidesRadiopharmaceuticals (peptide-based)
Industry: Biotech

Partnerships

MerckOrano MedJohnson & Johnson Innovation—JLABS incubator memberCQDM Quantum Leap program/GlycoNet support

Beyond the preview

Go deeper on 48Hour Discovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 48Hour Discovery.

Explore the full profile